Damora Therapeutics (DMRA)
NASDAQ:DMRA
Want to see DMRA full AI Analyst Report?
DMRA Stock Chart & Stats
$26.60
-$0.21(-3.82%)
At close: 4:00 PM EST
$26.60
-$0.21(-3.82%)
Day’s Range― - ―
52-Week Range$2.45 - $38.33
Previous CloseN/A
VolumeN/A
Average Volume (3M)5.26M
Market Cap
$1.44B
Enterprise Value$1.19B
Total Cash (Recent Filing)$257.62M
Total Debt (Recent Filing)$68.00K
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding60,303,210
10 Day Avg. Volume9,383,356
30 Day Avg. Volume5,257,093
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.12
Price to Sales (P/S)0.00
P/FCF Ratio-4.30
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-169.36K
Enterprise Value/Ebitda-5.88
Forecast
1Y Price Target
$43.20Price Target Upside62.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationLead asset DMR-001 is designed for simple subcutaneous administration with potent activity against both major CALR mutant types, which could provide a practical and efficacy advantage over a competing intravenous therapy that shows weaker activity against one mutant type.
Financial StrengthAcquisition by a larger company along with concurrent financing strengthened the balance sheet, supporting continued development of the mutCALR-focused portfolio.
Regulatory PathwayAnalyst notes planned regulatory filings and initial proof-of-concept clinical data for the lead candidate, which could enable a rapid transition into late-stage development if results are favorable.
Bears Say
Commercial Pressure From Larger RivalA larger rival developing an advanced mutCALR therapy brings greater commercial resources, increasing the risk of slower market uptake and pricing pressure for the company's product.
Competing ModalitiesIncyte's parallel development of a mutant CALR–directed monoclonal antibody and a bispecific T-cell engager adds alternative therapeutic approaches that may compete for the same patient population.
Competitive MaturityAn established competitor's more advanced program could constrain the company's market opportunity even if the candidate shows clinical advantages.
Damora Therapeutics News
DMRA FAQ
What was Damora Therapeutics’s price range in the past 12 months?
Damora Therapeutics lowest stock price was $2.45 and its highest was $38.33 in the past 12 months.
What is Damora Therapeutics’s market cap?
Damora Therapeutics’s market cap is $1.44B.
When is Damora Therapeutics’s upcoming earnings report date?
Damora Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 97 days.
How were Damora Therapeutics’s earnings last quarter?
Currently, no data Available
Is Damora Therapeutics overvalued?
According to Wall Street analysts Damora Therapeutics’s price is currently Undervalued.
Does Damora Therapeutics pay dividends?
Damora Therapeutics does not currently pay dividends.
What is Damora Therapeutics’s EPS estimate?
Damora Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Damora Therapeutics have?
Damora Therapeutics has 60,303,210 shares outstanding.
What happened to Damora Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Damora Therapeutics?
Currently, no hedge funds are holding shares in DMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Damora Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.20 (62.41% Upside)
$43.20 (62.41% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.34%
12-Months-Change
Fundamentals
Return on Equity
-134.39%
Trailing 12-Months
Asset Growth
-54.07%
Trailing 12-Months
Company Description
Damora Therapeutics
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.
DMRA Stock 12 Month Forecast
Average Price Target
$43.20
▲(62.41% Upside)
Technical Analysis
Ownership Overview
16.32% Insiders
6.42% Mutual Funds
0.03% Other Institutional Investors
76.63% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---